FY2025 EPS Estimates for Immunovant Decreased by Analyst

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Zacks Research decreased their FY2025 earnings per share estimates for Immunovant in a report released on Wednesday, February 26th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of ($2.82) for the year, down from their prior estimate of ($2.78). The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Zacks Research also issued estimates for Immunovant's Q4 2025 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.82) EPS, Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.91) EPS and FY2027 earnings at ($3.57) EPS.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.08).

A number of other equities analysts have also commented on IMVT. Wolfe Research lowered shares of Immunovant from an "outperform" rating to a "peer perform" rating in a report on Friday, January 3rd. Wells Fargo & Company cut their price target on Immunovant from $47.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, December 19th. HC Wainwright restated a "buy" rating and set a $51.00 price objective on shares of Immunovant in a research note on Friday, February 7th. Bank of America dropped their price objective on Immunovant from $48.00 to $45.00 and set a "buy" rating on the stock in a report on Wednesday, January 15th. Finally, Jefferies Financial Group started coverage on Immunovant in a research note on Monday. They set a "hold" rating and a $20.00 target price for the company. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Immunovant currently has an average rating of "Moderate Buy" and a consensus target price of $43.55.

Remove Ads

Immunovant Stock Performance

Shares of IMVT stock traded up $0.10 on Monday, hitting $19.52. The stock had a trading volume of 784,004 shares, compared to its average volume of 1,249,860. The stock's 50 day moving average is $21.94 and its 200-day moving average is $26.63. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -7.45 and a beta of 0.68. Immunovant has a 52-week low of $17.65 and a 52-week high of $35.97.

Insiders Place Their Bets

In other news, insider William L. Macias sold 2,383 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $23.83, for a total value of $56,786.89. Following the transaction, the insider now directly owns 359,408 shares in the company, valued at approximately $8,564,692.64. This trade represents a 0.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Salzmann sold 5,105 shares of Immunovant stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total transaction of $123,030.50. Following the completion of the transaction, the chief executive officer now directly owns 972,992 shares of the company's stock, valued at $23,449,107.20. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,510 shares of company stock valued at $656,886 over the last 90 days. 5.90% of the stock is owned by company insiders.

Institutional Trading of Immunovant

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC grew its stake in Immunovant by 19.6% during the 3rd quarter. FMR LLC now owns 12,537,571 shares of the company's stock worth $357,446,000 after buying an additional 2,053,688 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Immunovant by 53.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,117,234 shares of the company's stock worth $126,754,000 after acquiring an additional 1,786,217 shares during the last quarter. Deep Track Capital LP grew its position in shares of Immunovant by 38.0% during the fourth quarter. Deep Track Capital LP now owns 6,000,000 shares of the company's stock worth $148,620,000 after acquiring an additional 1,652,536 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Immunovant by 405.3% in the 4th quarter. JPMorgan Chase & Co. now owns 1,153,338 shares of the company's stock worth $28,568,000 after acquiring an additional 925,081 shares during the period. Finally, Two Seas Capital LP lifted its position in Immunovant by 123.4% in the 4th quarter. Two Seas Capital LP now owns 1,511,614 shares of the company's stock valued at $37,443,000 after purchasing an additional 835,000 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.